Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Name: Kaimen Rigor review — Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Item: Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.
Rating: 96
Author: Alpha1

Munir T, Girvan S, Cairns DA, Bloor A, Allsup D, Varghese AM, Gohil S, Paneesha S, Pettitt A, Eyre T, Fox CP, Forconi F, Kennedy B, Balotis C, Pemberton N, Sheehy O, Gribben J, Elmusharaf N, Gatto S, Preston G, Schuh A, Walewska R, Duley L, Webster N, Dalal S, Rawstron A, Howard D, Hockaday A, Jackson S, Greatorex N, Bell S, Stones D, Brown JM, Patten PEM, Hillmen P, UK CLL Trials Group

Paper source

Read full text

Embed this Rigor badge

Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 4 high issues for “Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.”

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Read alongside

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Read full text

DOI

10.1056/NEJMoa2504341

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f505727f-e41f-44bd-b1d5-f41acf0b2df1" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f505727f-e41f-44bd-b1d5-f41acf0b2df1/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 4 high issues for “Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

91749c85b25243e3cd99a9ace7a7588c381dad00eb27111ebdeaaae415ef8790

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Alpha¹ by Kaimen

Fetching the latest research

Kaimen Rigor reviewed

Rigor-Reviewed Manuscript

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Paper source

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Read full text

Embed this Rigor badge

Links back to this Kaimen Rigor review.

Alpha1 Editorial

This rigor review was examined and confirmed by Alpha1 Editorial · August 15, 2026

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint for the ibrutinib-venetoclax vs ibrutinib comparison is undetectable measurable residual disease (uMRD) in bone marrow, a surrogate biomarker. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking uMRD to clinical outcomes in this context. Although the trial also reports progression-free and overall survival as secondary endpoints, the primary efficacy claim for this comparison is based on uMRD.
“The primary endpoint for ibrutinib-venetoclax vs ibrutinib was uMRD (sensitivity 10-4) in BM at two years after initiation of therapy”
Find in source

Findings by category

201ArithmeticNumerical inconsistencies 202OverreachOverstated conclusions 03AuthenticityNone found 104DisclosureReporting gaps 05AvailabilityNone found · partly checked 06Copyedit13 minor suggestions

This Kaimen Rigor review uses Kaimen Rigor reviewers trained on a curated corpus of high-fidelity and retracted papers, with expert supervision and curation. It can still make mistakes; verify each finding against the source before relying on it.

This is a well-conducted phase III randomized trial with rigorous design, clear reporting of demographics, ethics, and statistical methods. The main weaknesses are the absence of a data availability statement, lack of explicit statistical software identification, and minor copyedit issues including an internal inconsistency in death counts and impossible percentages in supplementary tables.

Both reviewers agreed on all dimensions and study type (interventional). The statistics verification recomputed 5 tests consistently, but coverage is limited to tests with test statistics/df or effect estimates with CIs; threshold-only p-values and exact p-values were not machine-verified. The integrity check flagged an internal contradiction in death counts and impossible percentages in supplementary tables, which are not reflected in the dimension scores but are noted as action items.

Numerical inconsistencies

2 findings · worst low

Values that contradict each other or are impossible for the stated sample: recomputed p-values and test statistics, GRIM/GRIMMER checks on summary numbers, percentages against their own counts, totals against their parts, and estimates against their own confidence intervals.

Internal contradictions in the reported numbersAssessed
Mathematically impossible statisticAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

2 findings · worst high

Conclusions that reach past what the paper's own results support — including a significance claim that no longer holds when the statistic is recomputed, and efficacy resting on an unvalidated surrogate endpoint.

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

An adversarial read for patterns associated with data that may not be genuine: results that look too clean, implausibly large effects, duplicated data or images, and methods that do not match the results reported.

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Required detail the manuscript never states — study design, biological variables, ethics approval and consent, key resources, statistical reporting, data and code availability, and overall transparency.

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

The paper cites prior studies (GLOW, CAPTIVATE, CLARITY) and explains the biological rationale for combining ibrutinib and venetoclax. It acknowledges limitations of prior work, such as fixed-duration therapy and the need for individualized approaches. The premise is well-supported by the cited evidence.

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 2]

“In relapsed-refractory CLL, ibrutinib-venetoclax combination using eradication of detectable measurable residual disease (MRD) to guide duration of therapy, demonstrated that individualizing therapy was feasible.”

paraphrase[Discussion, paragraph 1]

“In FLAIR, MRD responses are more durable than reported in fixed-duration ibrutinib-venetoclax, possibly due to the personalized approach and longer exposure to ibrutinib-venetoclax.”

PASSReviewer 2· 90% conf

The introduction establishes a clear rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 3]

“Here, we present the pre-planned analysis comparing MRD-guided ibrutinib-venetoclax with ibrutinib and FCR with extended follow-up.”

paraphrase[Introduction, paragraph 2]

“Continuous BTK inhibitor therapy leads to improved outcomes but can induce resistance and toxicity.”

Randomization method and unit are clearly described (computer-generated minimization, 1:1:1). Blinding is not applicable as it is an open-label trial, which is stated. Power analysis is described for the primary endpoint (O'Brien-Fleming alpha-spending) and the powered secondary endpoint (90 events). Inclusion/exclusion criteria are summarized and detailed in the appendix. Outlier handling is addressed through the pre-specified analysis population (ITT) and safety population. Controls are the comparator arms (ibrutinib and FCR). Independent replication is not applicable for a single pivotal trial.

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

The trial design is rigorous: randomized, with a computer-generated minimization algorithm, open-label (stated), pre-specified endpoints, and a power analysis for the primary and powered secondary endpoints.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Abstract, Methods]

“In this phase III, multicenter, randomized-controlled, open-label trial”

paraphrase[Methods, Statistical Analysis]

“To ensure an overall significance level of 5% for this comparison allowing for interim analysis, the O’Brien and Fleming alpha-spending function was used. The results of the final analysis were significant if P≤0.048.”

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, open-label, with clear endpoints, statistical analysis plan, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Methods, Statistical Analysis]

“To ensure an overall significance level of 5% for this comparison allowing for interim analysis, the O’Brien and Fleming alpha-spending function was used.”

paraphrase[Methods, Trial Design and Patients]

“Key inclusion criteria included previously untreated CLL or small lymphocytic lymphoma requiring treatment; considered fit for FCR, between 18 and 75 years of age.”

The paper reports sex (male/female), age (median and IQR), ethnicity, and other baseline characteristics in Table 1. Since both sexes are enrolled, sex_justified is not applicable. Age, weight, and health status are reported (age, performance status, creatinine clearance). Demographics are adequately reported.

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and key disease characteristics. Sex is reported for both sexes, so no single-sex justification is needed.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Results, Patients]

“The median age was 62 years (IQR, 56 to 67); 247 (31.4%) > 65 years.”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and disease stage.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Table 1]

“Median Age (IQR) - yr 62 (57-67) 62 (56-67) 62 (55-67) 62 (56-67)”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

The paper states that a national ethics committee and institutional review boards approved the protocol, and participants provided written informed consent. Compliance with the Declaration of Helsinki is stated. This meets the criteria for human research.

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Ethical approval is documented: a national ethics committee and institutional review boards approved the protocol, and written informed consent was obtained. The trial was performed in accordance with the Declaration of Helsinki.

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

The trial uses ibrutinib and venetoclax as investigational products; they are named with manufacturers (Johnson and Johnson, AbbVie) and dosing regimens. The statistical software is not explicitly named in the main text, but the analysis methods are described. Since this is a drug trial, the bench criteria (antibodies, cell lines, mycoplasma, organisms) are not applicable. Reagents are scored against the investigational products, which are adequately identified.

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

The investigational products (ibrutinib and venetoclax) are identified with manufacturer and dosing regimen, and the statistical software is identified. No other biological/chemical resources are used.

Evidence

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

“Ibrutinib monotherapy was administered orally 420 mg/day for six years.”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named in the main text.

PASSReviewer 2· 85% conf

The investigational products (ibrutinib and venetoclax) are identified with manufacturer and dosing, and statistical software is identified.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Ibrutinib monotherapy was administered orally 420 mg/day for six years. In the ibrutinib-venetoclax group, ibrutinib was administered orally 420 mg/day for 8 weeks before venetoclax was incrementally escalated to 400 mg/day over 5 weeks.”

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

Tests are named (binary logistic penalized regression, Cox proportional hazards, Kaplan-Meier). Assumptions are handled by design (Cox model, penalized regression). Exact p-values are reported for primary and powered secondary endpoints (e.g., p<0.001). Effect sizes are reported with 95% CIs. Statistical software is not explicitly named, but this is a minor omission. Data presentation includes Kaplan-Meier curves and forest plots, which is appropriate for a clinical trial. Mathematical plausibility is not applicable for large-N continuous outcomes.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Statistical methods are appropriate and well-described: logistic regression for the primary endpoint, Cox proportional hazards for survival, Kaplan-Meier estimates, and exact p-values for primary comparisons. Effect sizes are reported with confidence intervals.

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract, Results]

“172/260 ibrutinib-venetoclax (66.2%) (p<0.001)”

paraphrase[Abstract, Results]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for primary endpoints and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

paraphrase[Results, Efficacy]

“HR for progression-free survival (ibrutinib-venetoclax vs. ibrutinib) was 0.29 (95%CI, 0.17 to 0.49; P<0.001)”

No data availability statement is present in the paper. The protocol is mentioned as available at NEJM.org, but this does not constitute a data availability statement for the trial data. No repository deposits or accession numbers are provided. Code sharing is not applicable as no bespoke code is described.

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned. This is a reporting gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present.

paraphrase[Methods, Trial Design and Patients]

“The authors designed the trial, vouch for the accuracy and completeness of the data, and adherence to the protocol (available at NEJM.org).”

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present.

Trial registration numbers are provided. Methods are detailed enough for replication. Limitations are discussed (e.g., open-label design, cross-trial comparisons, need for longer follow-up). Conclusions are proportional to the evidence. Funding sources and conflicts of interest are disclosed. Reporting guidelines are not explicitly mentioned, but the paper follows CONSORT-like structure.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered (ISRCTN01844152, EudraCT 2013-001944-76), methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

paraphrase[Abstract, Conclusion]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 4]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

paraphrase[Abstract]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 5]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

Registered (2 IDs: ISRCTN). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 20 references by DOI: 18 verified — 2 no DOI (shown, not verified).

Copyediting

13 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 13 minor suggestions below.

13 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

The published work is methodologically robust and the main conclusions are supported by the reported analyses. An informed reader should weigh the missing data availability statement and the minor internal inconsistencies (death counts, impossible percentages) as reporting gaps that warrant correction or clarification, but they do not undermine the primary efficacy findings.

1.
HIGHrigor
Reconcile the death counts: the Safety section states 'Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR' (sum 73), conflicting with the abstract and Results which report 11, 26, and 39 (sum 76). Correct the inconsistent numbers in the Safety section or elsewhere.
An internal contradiction in a key safety outcome is a validity threat that could mislead readers and warrants a correction.
2.
HIGHrigor
Correct the impossible percentages in Supplementary Tables S20 and S21 (e.g., 115.2% and 120.8%) which exceed 100% for a proportion.
Impossible statistics indicate a calculation or reporting error that undermines the credibility of the supplementary data.
3.
HIGHdata code
Add a data availability statement to the manuscript (e.g., in Methods or a dedicated section) specifying how de-identified patient data can be accessed (e.g., via a data access committee or repository like YODA/Vivli) and the conditions for access.
The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals and funders.
4.
HIGHstatistics
Explicitly name the statistical software used (e.g., SAS, R) with version numbers in the Statistical Analysis section.
Identifying the software is essential for reproducibility and is a standard reporting requirement.
5.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a separate section, and provide the checklist as supplementary material.
Explicitly referencing CONSORT improves transparency and is expected for randomized trials.
6.
MEDIUMcopyedit
Fix the spacing errors in the Abstract Results (e.g., '1 27 /263 FCR ( 48 . 3 %)' should be '127/263 FCR (48.3%)', '1 72 /260 ibrutinib - venetoclax ( 66.2 %)' should be '172/260 ibrutinib-venetoclax (66.2%)', '0. 64 (95% CI, 0. 39 to 1.05 )' should be '0.64 (95% CI, 0.39 to 1.05)').
Spacing errors in key results detract from professionalism and readability.
7.
MEDIUMcopyedit
Remove the stray DOI fragment at the end of the References ('0.1056/nejm200012283432602.').
Stray text in references is a formatting error that should be corrected.
8.
MEDIUMcopyedit
Ensure consistent formatting of fractions and percentages throughout the manuscript (e.g., '70 / 25 7 [ 27.2 %]' should be '70/257 [27.2%]').
Consistent formatting improves clarity and avoids confusion.
9.
LOWcopyedit
Standardize the use of 'n' vs 'N' in Table 2 (e.g., 'FCR (n=239) I (n=260) I+V (n=257)').
Minor capitalization inconsistency is a polish issue.
10.
LOWdata code
Consider depositing the statistical analysis code (if any) in a public repository with a DOI to enhance reproducibility.
Sharing analysis code would strengthen reproducibility, though it is not mandatory.
11.
LOWreporting
Clarify the availability of the trial protocol and statistical analysis plan (e.g., at NEJM.org) in a dedicated statement.
Providing a clear link to the protocol and SAP improves transparency.

Full text (132,334 chars · analyzed ~57%, head + tail)Analyzed: Aug 15, 2026

Start the discussion on JRNLClub

Community discussion on jrnlclub.com

Read alongside

Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.

Read full text

DOI

10.1056/NEJMoa2504341

Share this Kaimen Rigor review

Post on X Share on LinkedIn Share via Email

Embed this Rigor badge

<a href="https://alpha1science.com/verify/f505727f-e41f-44bd-b1d5-f41acf0b2df1" target="_blank" rel="noopener">
  <img src="https://alpha1science.com/verify/f505727f-e41f-44bd-b1d5-f41acf0b2df1/badge" alt="Kaimen Rigor review — 3.25★ (Adequate), 0 critical, 4 high issues for “Measurable Residual Disease-Guided Therapy for Chronic Lymphocytic Leukemia.”" width="440" height="104" style="max-width:100%;height:auto" />
</a>

Every embed links back to this Kaimen Rigor review.

Record fingerprint

91749c85b25243e3cd99a9ace7a7588c381dad00eb27111ebdeaaae415ef8790

Verify via API

Issued Aug 15, 2026Engine 7.39.0

Alpha1 assesses methodological rigor, not the importance of the findings. See how we calibrate →

Kaimen Rigor review

Kaimen Rigor reviewed

3.25 / 5

Adequate — real issues to address

Interventional Study

Critical

High-priority

How this rating was calculated▸

Started at 5★ — deductions

IntegrityIntegrity concern ×2−1★
ClaimsEfficacy rests on an unvalidated surrogate endpoint−0.5★
ReportingData & code availability partially met−0.25★

Model-reported confidence: highReviewer agreement: highEngine: 7.39.0Source: full text

Not verified in this report

No data or code availability links were detected to verify.

Biggest issues

01Efficacy rests on an unvalidated surrogate endpoint
highOverreachreviewer-assessedFull detail
The primary endpoint for the ibrutinib-venetoclax vs ibrutinib comparison is undetectable measurable residual disease (uMRD) in bone marrow, a surrogate biomarker. The paper does not provide evidence of target engagement at the tested dose (e.g., PK/PD) nor cite validated evidence linking uMRD to clinical outcomes in this context. Although the trial also reports progression-free and overall survival as secondary endpoints, the primary efficacy claim for this comparison is based on uMRD.
“The primary endpoint for ibrutinib-venetoclax vs ibrutinib was uMRD (sensitivity 10-4) in BM at two years after initiation of therapy”
Find in source

Findings by category

Numerical inconsistencies

2 findings · worst low

Internal contradictions in the reported numbersAssessed
Mathematically impossible statisticAssessed

Recomputed 5 tests: 5 consistent, 0 inconsistent; 5 via agent-written checks.

Overstated conclusions

2 findings · worst high

Efficacy rests on an unvalidated surrogate endpointAssessed
Conclusions only partially backed by the presented evidenceAssessed

8 major claims checked against the paper's own evidence: 2 only partially supported (evidence backs part of the claim; gaps or caveats remain); the rest adequately supported.

Premise concern: surrogate not validated for clinical benefit.

Data authenticity concerns

None found

Checked — nothing surfaced.

Reporting gaps

1 finding · worst medium

Data/code availability incompleteAssessed

Eight Dimensions7 pass · 1 warn

Sub-criteria

prior work citedADEQUATE

premise rationaleADEQUATE

limitations addressedADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The introduction establishes a clear scientific rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 2]

paraphrase[Discussion, paragraph 1]

“In FLAIR, MRD responses are more durable than reported in fixed-duration ibrutinib-venetoclax, possibly due to the personalized approach and longer exposure to ibrutinib-venetoclax.”

PASSReviewer 2· 90% conf

The introduction establishes a clear rationale for the study, citing prior work on ibrutinib-venetoclax and MRD-guided therapy, and the hypothesis follows logically.

Evidence

paraphrase[Introduction, paragraph 2]

“GLOW and CAPTIVATE trials studied ibrutinib-venetoclax 15 months fixed-duration combination, leading to improved progression-free survival.”

paraphrase[Introduction, paragraph 3]

“Here, we present the pre-planned analysis comparing MRD-guided ibrutinib-venetoclax with ibrutinib and FCR with extended follow-up.”

paraphrase[Introduction, paragraph 2]

“Continuous BTK inhibitor therapy leads to improved outcomes but can induce resistance and toxicity.”

Sub-criteria

controlsADEQUATE

power analysisADEQUATE

blinding levelsADEQUATE

outlier handlingADEQUATE

randomization unitADEQUATE

inclusion exclusionADEQUATE

randomization methodADEQUATE

replicate distinctionN/A

independent replicationN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 95% conf

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Abstract, Methods]

“In this phase III, multicenter, randomized-controlled, open-label trial”

paraphrase[Methods, Statistical Analysis]

PASSReviewer 2· 95% conf

The trial design is rigorous: randomized, open-label, with clear endpoints, statistical analysis plan, and pre-specified inclusion/exclusion criteria.

Evidence

paraphrase[Methods, Randomization and Procedures]

“Participants were randomly assigned (1:1:1) to receive FCR, ibrutinib or ibrutinib-venetoclax with the use of a computer-generated minimization algorithm with a random element.”

paraphrase[Methods, Statistical Analysis]

“To ensure an overall significance level of 5% for this comparison allowing for interim analysis, the O’Brien and Fleming alpha-spending function was used.”

paraphrase[Methods, Trial Design and Patients]

“Key inclusion criteria included previously untreated CLL or small lymphocytic lymphoma requiring treatment; considered fit for FCR, between 18 and 75 years of age.”

Sub-criteria

demographicsADEQUATE

sex reportedADEQUATE

sex justifiedN/A

age weight healthADEQUATE

housing conditionsN/A

species strain sourceN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and key disease characteristics. Sex is reported for both sexes, so no single-sex justification is needed.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Results, Patients]

“The median age was 62 years (IQR, 56 to 67); 247 (31.4%) > 65 years.”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

PASSReviewer 2· 90% conf

Demographic and clinical characteristics are well reported, including age, sex, ethnicity, and disease stage.

Evidence

“Gender Male 187 (71.1%) 186 (70.7%) 186 (71.5%) 559 (71.1%) Female 76 (28.9%) 77 (29.3%) 74 (28.5%) 227 (28.9%)”

Table 1Find in source

paraphrase[Table 1]

“Median Age (IQR) - yr 62 (57-67) 62 (56-67) 62 (55-67) 62 (56-67)”

“Ethnicity White 240 (91.3%) 241 (91.6%) 235 (90.4%) 716 (91.1%)”

Table 1Find in source

Sub-criteria

iacuc statementN/A

informed consentADEQUATE

irb ethics statementADEQUATE

regulatory complianceADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

PASSReviewer 2· 95% conf

Ethics approval and informed consent are clearly documented.

Evidence

paraphrase[Methods, Trial Design and Patients]

“A national ethics committee and institutional review boards approved the protocol.”

“Participants provided written informed consent.”

MethodsFind in source

“The trial was performed in accordance with the Declaration of Helsinki.”

MethodsFind in source

Sub-criteria

mycoplasma testingN/A

reagents identifiedADEQUATE

organisms identifiedN/A

antibodies identifiedN/A

cell line authenticationN/A

software tools identifiedINADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 85% conf

Evidence

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

“Ibrutinib monotherapy was administered orally 420 mg/day for six years.”

MethodsFind in source

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named in the main text.

PASSReviewer 2· 85% conf

The investigational products (ibrutinib and venetoclax) are identified with manufacturer and dosing, and statistical software is identified.

Evidence

paraphrase[Methods, Randomization and Procedures]

paraphrase[Funding]

“Study drug (ibrutinib) was provided by Johnson and Johnson and study drug (venetoclax) was provided by AbbVie.”

absence[Methods, Statistical Analysis]

Statistical software is not explicitly named.

Sub-criteria

tests namedADEQUATE

exact p valuesADEQUATE

effect sizes ciADEQUATE

data presentationADEQUATE

software identifiedINADEQUATE

assumptions verifiedADEQUATE

mathematical plausibilityN/A

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract, Results]

“172/260 ibrutinib-venetoclax (66.2%) (p<0.001)”

paraphrase[Abstract, Results]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

PASSReviewer 2· 90% conf

Statistical methods are appropriate and well-described, with exact p-values for primary endpoints and effect sizes with confidence intervals.

Evidence

paraphrase[Methods, Statistical Analysis]

“We made comparisons using a binary logistic penalized regression model with adjustment for the minimization factors (excluding trial center).”

paraphrase[Abstract]

“Hazard ratio (HR) for progression-free survival was: 0.13 (95% CI, 0.08 to 0.21, p<0.001) for ibrutinib-venetoclax vs FCR”

paraphrase[Results, Efficacy]

“HR for progression-free survival (ibrutinib-venetoclax vs. ibrutinib) was 0.29 (95%CI, 0.17 to 0.49; P<0.001)”

Sub-criteria

code sharingN/A

accession numbersN/A

repository depositN/A

data availability statementNOT REPORTED

Per reviewer (2) — the votes behind the verdict

WARNReviewer 1· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned. This is a reporting gap for a clinical trial.

Evidence

absence[Entire paper]

No data availability statement is present.

paraphrase[Methods, Trial Design and Patients]

“The authors designed the trial, vouch for the accuracy and completeness of the data, and adherence to the protocol (available at NEJM.org).”

WARNReviewer 2· 80% conf

The paper does not include a data availability statement, and no data or code repositories are mentioned.

Evidence

absence[Entire paper]

No data availability statement is present.

Sub-criteria

funding coiADEQUATE

trial registrationADEQUATE

reporting guidelineINADEQUATE

methods completenessADEQUATE

all outcomes reportedADEQUATE

limitations discussedADEQUATE

conclusions proportionalADEQUATE

Per reviewer (2) — the votes behind the verdict

PASSReviewer 1· 90% conf

The trial is registered (ISRCTN01844152, EudraCT 2013-001944-76), methods are detailed, limitations are discussed, conclusions are proportional, and funding/COI are disclosed.

Evidence

paraphrase[Abstract, Conclusion]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 4]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

PASSReviewer 2· 90% conf

The trial is registered, methods are detailed, limitations are discussed, and conclusions are proportional to the evidence.

Evidence

paraphrase[Abstract]

“FLAIR ISRCTN Registry number, ISRCTN01844152; EudraCT number, 2013-001944-76.”

paraphrase[Discussion, paragraph 5]

“These findings should also be interpreted in the context of the relatively young trial population, in whom longer term follow up is essential to evaluate the potential for functional cure.”

“Primary financial support was from Cancer Research UK (C18027/A15790).”

FundingFind in source

Registered (2 IDs: ISRCTN). No reporting guideline cited.

Broken references and links

None found · partly checked

References checked against Crossref, OpenAlex and Retraction Watch for retractions and resolvability, plus declared data and code links probed for whether they resolve to content matching the paper.

Nothing surfaced — but not everything feeding this category ran (missing: data/code link verification), so read this as a partial clean bill.

Checked 20 references by DOI: 18 verified — 2 no DOI (shown, not verified).

Copyediting

13 minor

Wording, consistency and formatting errors that need correcting before submission.

No major wording or formatting errors. 13 minor suggestions below.

13 copyedit issues flagged: mostly typo, consistency.

Kaimen Rigor Action ItemsFinal pass before journal submission

1.
HIGHrigor
Reconcile the death counts: the Safety section states 'Eleven deaths were seen in participants treated with ibrutinib-venetoclax, 25 with ibrutinib and 37 with FCR' (sum 73), conflicting with the abstract and Results which report 11, 26, and 39 (sum 76). Correct the inconsistent numbers in the Safety section or elsewhere.
An internal contradiction in a key safety outcome is a validity threat that could mislead readers and warrants a correction.
2.
HIGHrigor
Correct the impossible percentages in Supplementary Tables S20 and S21 (e.g., 115.2% and 120.8%) which exceed 100% for a proportion.
Impossible statistics indicate a calculation or reporting error that undermines the credibility of the supplementary data.
3.
HIGHdata code
Add a data availability statement to the manuscript (e.g., in Methods or a dedicated section) specifying how de-identified patient data can be accessed (e.g., via a data access committee or repository like YODA/Vivli) and the conditions for access.
The absence of a data availability statement is a reporting gap for a clinical trial and is required by most journals and funders.
4.
HIGHstatistics
Explicitly name the statistical software used (e.g., SAS, R) with version numbers in the Statistical Analysis section.
Identifying the software is essential for reproducibility and is a standard reporting requirement.
5.
MEDIUMreporting
Mention adherence to a reporting guideline such as CONSORT in the Methods or a separate section, and provide the checklist as supplementary material.
Explicitly referencing CONSORT improves transparency and is expected for randomized trials.
6.
MEDIUMcopyedit
Fix the spacing errors in the Abstract Results (e.g., '1 27 /263 FCR ( 48 . 3 %)' should be '127/263 FCR (48.3%)', '1 72 /260 ibrutinib - venetoclax ( 66.2 %)' should be '172/260 ibrutinib-venetoclax (66.2%)', '0. 64 (95% CI, 0. 39 to 1.05 )' should be '0.64 (95% CI, 0.39 to 1.05)').
Spacing errors in key results detract from professionalism and readability.
7.
MEDIUMcopyedit
Remove the stray DOI fragment at the end of the References ('0.1056/nejm200012283432602.').
Stray text in references is a formatting error that should be corrected.
8.
MEDIUMcopyedit
Ensure consistent formatting of fractions and percentages throughout the manuscript (e.g., '70 / 25 7 [ 27.2 %]' should be '70/257 [27.2%]').
Consistent formatting improves clarity and avoids confusion.
9.
LOWcopyedit
Standardize the use of 'n' vs 'N' in Table 2 (e.g., 'FCR (n=239) I (n=260) I+V (n=257)').
Minor capitalization inconsistency is a polish issue.
10.
LOWdata code
Consider depositing the statistical analysis code (if any) in a public repository with a DOI to enhance reproducibility.
Sharing analysis code would strengthen reproducibility, though it is not mandatory.
11.
LOWreporting
Clarify the availability of the trial protocol and statistical analysis plan (e.g., at NEJM.org) in a dedicated statement.
Providing a clear link to the protocol and SAP improves transparency.

Full text (132,334 chars · analyzed ~57%, head + tail)Analyzed: Aug 15, 2026